However, the primary role of TRPV4 in hypoxic pulmonary vasoconstriction indicates the detriment of TRPV4 inhibition to patients with lung disease (Yang et al., 2012; Morty and Kuebler, 2014; Goldenberg et al., 2015a). This evidence concerns the gene TRPV4 and lung disorder.